ProPhase Labs, Inc.
ProPhase Labs, Inc. is a U.S.-based life sciences and consumer health company with operations spanning diagnostic services, personal genomics, and branded dietary supplements. Through subsidiaries including ProPhase Diagnostics and Nebula Genomics, it combines laboratory testing, DNA sequencing, and consumer wellness products under one corporate structure.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueConsumer DNA sequencing and genetic testing services offered through Nebula Genomics and DNA Complete.
Laboratory testing services, including COVID-19 and other molecular diagnostics.
Branded OTC health and dietary supplement products sold under the TK Supplements line.
Development and commercialization of novel drugs, compounds, diagnostics, and related IP.
Customers
The company sells primarily to consumers seeking genetic insights, health information, and wellness products, with Nebula and DNA Complete serving the personal genomics market. It also serves patients, physicians, and payors through diagnostic testing activities, while TK Supplements targets retail consumers buying OTC health and vitality products.
Buy DNA sequencing and genetic testing for ancestry, health risk, and trait insights.
Buy laboratory testing services, historically including COVID-19 and molecular diagnostics.
Buy TK Supplements products for energy, sexual vitality, and general wellness.
Partners or license holders involved in drug, compound, and diagnostic commercialization.
Strategy
The company is focused on building and commercializing multiple health-related businesses, including genomics, diagnostics, supplements, and licensed product candidates. Its strategy also includes exploring new product technologies and financing growth through equity, debt, collaborations, or other sources as needed.
These businesses provide recurring consumer-facing revenue opportunities and brand-building potential.
Drug, compound, and diagnostic development can create higher-value future revenue streams if successful.
The business mix includes development-stage activities that require funding before they can scale.
Geography
ProPhase Labs is headquartered in the United States and its operating footprint is centered there, including laboratory space in New Jersey and consumer-facing activities in the U.S. The company also describes Nebula Genomics as a personal genomics business with a broader market reach, but the disclosed operating base and core revenue exposure remain U.S.-centric.
Risks
The company faces execution risk across several businesses, including consumer complaints, sequencing delays, reimbursement disputes, and the challenge of replacing diagnostic revenue with other lines. It also carries development-stage, financing, and litigation risk, while any digital-asset activity could add volatility and operational complexity.
- Insurance reimbursement and collections riskImpact: Critical
Diagnostic revenue depends on payor reimbursement and timely claim collection.
Exposure: ProPhase Diagnostics
- Financing and liquidity dependenceImpact: HighLikelihood: High
Development and commercialization activities require external capital before scale.
Exposure - Consumer complaints and reputational damageImpact: HighLikelihood: Medium
DNA testing customers rely on trust, timely results, and data handling quality.
Exposure: Nebula Genomics and DNA Complete
- Sequencing and fulfillment delaysImpact: HighLikelihood: Low
A change in sequencing lab can delay results and increase service backlogs.
Exposure: Personal genomics operations
- Litigation and privacy exposureImpact: MediumLikelihood: Low
Genetic data handling can trigger privacy claims and regulatory scrutiny.
Exposure: Nebula Genomics and customer data
- Digital asset volatilityImpact: MediumLikelihood: Low
Any crypto treasury activity can create mark-to-market and custody risk.
Exposure: Potential digital asset holdings
Accounting
Judgemental itemsDiagnostics, sequencing, and consumer products may recognize revenue at different points in time.
Impact: Affects quarterly comparability and reported growth across segments
Diagnostic services depend on collecting insurance-related receivables.
Impact: Can materially affect cash flow and bad debt expense
Privacy litigation and reimbursement disputes may require accruals or disclosures.
Impact: Can affect expenses, liabilities, and uncertainty disclosures
Management estimates fair value and expense recognition for equity awards.
Impact: Impacts operating expenses and dilution analysis
Acquired businesses, licenses, and development assets may require periodic testing.
Impact: Can create non-cash charges if expected cash flows weaken
Similar listed companies
Publicly listed companies with a comparable business focus.
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Profound Medical Corp.
PROF · Surgical & Medical Instruments & Apparatus
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
ProQR Therapeutics N.V.
PRQR · Pharmaceutical Preparations
Prenetics Global Ltd
PRE · Pharmaceutical Preparations
Prenetics Global Ltd is a U.S.-listed health sciences company focused on consumer health, wellness, and longevity products through its IM8 brand and the CircleDNA testing business.
Tempus AI, Inc.
TEM · Services-Computer Programming, Data Processing, Etc.
Last updated: 24/09/2026